Open Veils · Answer
Effectiveness of ivermectin
The suppressed record shows ivermectin has a broad-spectrum biological profile extending well beyond its approved label — antiparasitic, antiviral, anti-inflammatory, and now oncological. The COVID controversy obscured a substantial body of contested clinical and mechanistic evidence. Researchers like Peter McCullough and Pierre Kory argued large positive trials were systematically excluded from meta-analyses used to inform policy. The compound's patent-expired, generic status created structural incentives against its adoption.
Evidence
- Dr. Pierre Kory, before the U.S. Senate in December 2020, testified that ivermectin demonstrated near-miraculous efficacy against COVID-19 across multiple early treatment trials, citing data from South American and Indian health systems.
- The Surgisphere scandal, in which fraudulent data briefly polluted The Lancet and NEJM, demonstrated how low-quality pro-establishment data could move regulatory needle while identically uncertain pro-ivermectin data was dismissed.
- Beyond COVID, ivermectin's antiparasitic credentials are genuinely established.
- The oncology frontier is where the compound's suppressed profile becomes most provocative.
- His organization, the Front Line COVID-19 Critical Care Alliance (FLCCC), compiled a living meta-analysis they argued showed consistent benefit that was ignored by NIH and WHO guideline panels.